GERON CORPORATION (NASDAQ:GERN) Files An 8-K Other Events
Item 8.01. Other Events.
On April 10, 2017, Geron Corporation issued a press release
entitled Geron Announces Completion of Second Internal Data
Reviews for Imetelstat Trials Being Conducted by Janssen. A copy
of the press release is attached as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | ||
| 99.1 | Press release, dated April 10, 2017. |
1
About GERON CORPORATION (NASDAQ:GERN)
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Imetelstat exhibits relatively preferential inhibition of the clonal proliferation of malignant progenitor cells in nonclinical studies. Janssen is engaged in the development of Imetelstat with over two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. GERON CORPORATION (NASDAQ:GERN) Recent Trading Information
GERON CORPORATION (NASDAQ:GERN) closed its last trading session up +0.03 at 2.15 with 1,297,873 shares trading hands.